That is the title of a KFF article revealed final week. The outcomes are based mostly on KFF’s 2024 Employer Health Benefits Survey. They write:
For KFF’s survey of two,142 randomly chosen corporations, officers from these with 500 or extra staff had been requested how a lot of the rebates negotiated by [pharmacy benefit managers] PBMs returned to the corporate as financial savings. About 19% stated they acquired many of the rebates, 27% stated some, and 16% stated little. Thirty-seven % of the respondents didn’t know.
While a bigger share of officers from the most important corporations stated they acquired most or a few of the rebates, the solutions — and their distinction with the testimony of PBM leaders — replicate the confusion or ignorance of employers about what their drug profit managers do, stated survey chief Gary Claxton, a senior vice chairman at KFF, a well being info nonprofit that features KFF Health News.
“I don’t suppose they will ever know all of the methods the cash strikes round as a result of there are such a lot of layers, between the wholesalers and the pharmacies and the producers,” he stated…“Employers are typically annoyed by the shortage of transparency into all the costs on the market,” Claxton stated. “They can’t truly know what’s true.”
Do you suppose PBMs result in greater or decrease pharmacy value?